News Chart PharmAbcine Inc.

Equities

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-01-18 pm EST			5-day change	1st Jan Change
2,915 ^KRW	-8.91%		-.--%	-22.27%

Jan. 24	PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors	CI
2023	PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding	CI

ef83bea.Bjv1fDm05mjfsmX0tLmcEsSrV7d6c5J2yzJ8Q_LpbYM.M1KxJVDOvDCQ5y2xgNHdUJLDEZo_Nf5H-1MRM52sMuU1cYE4ddygLe_4Dg~76e27a2953a220194a8d0119665505d3